RE: In talks with BIG PHARAMA27 May 2022 05:27
Deals with Big Pharma would surely be attractive in terms of being able to rapidly ramp up our position in the US ,particularly in respect of this first successful application,which would take some time , massive investment,(resulting in substantial dilution,substantial execution risk with no guarantees that our corporate development in the US would be as successful as hoped for.To licence to big Pharma would result in a substantial upfront payment,substantial milestones ,no dilution& ,if well negotiated,a very decent mid teen digit royalty.The funds received will enable us to develop & accelerate global roll out of all applications & ensure rapid growth with reduced risk.My view is that this outcome is best for AGL in that it immediately eliminates the dilution risk,while providing an immediate cash injection & a greater chance of more rapid success in the US leaving us to do what we have now proven we do best.